Peter Blume-Jensen insider trades
Open-market stock purchases and sales by Peter Blume-Jensen, President and CEO at Acrivon Therapeutics, Inc, from SEC Form 4 filings since Nov 14, 2022.
Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -18%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| May 21, 2026 | ACRV Acrivon Therapeutics, Inc | Sold (not open market) | $24.6K |
| May 18, 2026 | ACRV Acrivon Therapeutics, Inc | Bought (not open market) | — |
| May 18, 2026 | ACRV Acrivon Therapeutics, Inc | Bought (not open market) | — |
| May 14, 2026 | ACRV Acrivon Therapeutics, Inc | Sold (not open market) | $2.4K |
| May 14, 2026 | ACRV Acrivon Therapeutics, Inc | Sold (not open market) | $941 |
| Mar 1, 2026 | ACRV Acrivon Therapeutics, Inc | Bought (not open market) | — |
| Mar 1, 2026 | ACRV Acrivon Therapeutics, Inc | Bought (not open market) | — |
| Feb 21, 2026 | ACRV Acrivon Therapeutics, Inc | Sold (not open market) | $21.8K |
| Feb 14, 2026 | ACRV Acrivon Therapeutics, Inc | Sold (not open market) | $2.1K |
| Feb 14, 2026 | ACRV Acrivon Therapeutics, Inc | Sold (not open market) | $944 |
| Jan 14, 2026 | ACRV Acrivon Therapeutics, Inc | Bought | $82.1K |
| Nov 21, 2025 | ACRV Acrivon Therapeutics, Inc | Sold (not open market) | $45.8K |
| Nov 14, 2025 | ACRV Acrivon Therapeutics, Inc | Sold (not open market) | $134K |
| Nov 14, 2025 | ACRV Acrivon Therapeutics, Inc | Sold (not open market) | $1.1K |
Companies traded
- ACRV Acrivon Therapeutics, Inc: 1 buy, last May 21, 2026